Medeon Biodesign, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was TWD 298.32 million compared to TWD 68.96 million a year ago. Net loss was TWD 433.76 million compared to net income of TWD 2,078.19 million a year ago.

Basic loss per share from continuing operations was TWD 4.7143. Diluted loss per share from continuing operations was TWD 4.7143. Basic loss per share was TWD 4.7143 compared to basic earnings per share of TWD 22.6478 a year ago.

Diluted loss per share was TWD 4.7143 compared to diluted earnings per share of TWD 22.5716 a year ago.